G0-C14

G0-C14 is an ionizable cationic lipid that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.¹ Administration of LNPs containing G0-C14 and encapsulating siRNA targeting CaMKIIγ increases plaque stability and promotes macrophage efferocytosis of apoptotic cells within plaques in a fat-fed Ldlr^-/- mouse model of atherosclerosis. LNPs containing G0-C14 and encapsulating siRNA targeting IL11 reduce fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis when administered via inhalation.² LNPs containing G0-C14 and conjugated to an enhanced glucagon-like peptide 1 (GLP-1) peptide (eGLP-1) selectively accumulate in the pancreas in mice.³ eGLP-1-conjugated and G0-C14-containing LNPs encapsulating CD274 mRNA, which encodes programmed cell death 1 (PD-L1), induce PD-L1 expression and localization to the pancreatic β cell surface and decrease severe insulitis in mice.

WARNING This product is not for human or veterinary use.

1. Huang, X., Liu, C., Kong, N., et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nat. Protoc. 17(3), 748-780 (2022).

2. Bai, X., Zhao, G., Chen, Q., et al. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci. Adv. 8(25), eabn7162 (2022).

3. Enriquez, J.R., Zhou, Z., Nelson, J.B., et al. Messenger RNA delivery to islet β cells using conjugated lipid nanoparticles. Cell Rep. Med. 7, 102634 (2026).